Advances and Challenges in Targeting BET Proteins in Solid Tumors

BET proteins, particularly BRD4, have emerged as pivotal drivers of oncogenic transcription in various solid tumors, presenting a promising but complex target for cancer therapy. Initial attempts to inhibit BET proteins focused on first-generation inhibitors such as JQ1, molibresib, and birabresib. While these compounds demonstrated potent displacement of BRD4 and suppression of the oncogene MYC in preclinical settings, their clinical impact proved modest, primarily due to significant toxicities like thrombocytopenia and the rapid development of drug resistance mechanisms.

Resistance arises through sophisticated cellular adaptations, including isoform switching of BRD4 and activation of compensatory signaling pathways such as PI3K/AKT and WNT. This resistance, coupled with the intricate transcriptional circuitry characteristic of solid tumors—distinct from hematological malignancies—has dampened hopes for BET inhibitors as monotherapies.

To address these challenges, the field is now pivoting towards next-generation strategies with enhanced specificity and efficacy. Among these, BD2-selective inhibitors aim to spare BD1, effectively reducing hematologic toxicities while maintaining robust anti-tumor effects. Proteolysis targeting chimeras (PROTACs) like ARV-771 and MZ1 have gained attention for their ability to degrade BET proteins entirely, potentially circumventing resistance associated with isoform variability.

Further innovation includes bivalent BET inhibitors that simultaneously engage both bromodomains, amplifying binding affinity and tumor suppression. Researchers are also exploring dual-function inhibitors that target BET proteins alongside kinases or histone deacetylases, as well as agents that disrupt BRD4-mediated phase separation at super-enhancers—critical hubs of oncogenic transcription.

Combination therapies represent a vital avenue to amplify therapeutic efficacy. Pairing BET inhibitors with PARP inhibitors has shown synergistic effects by exploiting DNA repair vulnerabilities, particularly in triple-negative breast and ovarian cancers. Similarly, combining BET inhibitors with androgen receptor antagonists improves outcomes in castration-resistant prostate cancer. Immune checkpoint inhibition in conjunction with BET targeting displays promising preclinical results, although toxicity remains a significant concern.

Clinical trials underscore both the potential and hurdles of BET inhibition. Agents like molibresib exhibited measurable activity in NUT carcinoma but required intermittent dosing to manage toxicity. Combinations such as ZEN-3694 with enzalutamide or talazoparib indicate early clinical signals of benefit, but many studies have been discontinued due to limited single-agent activity and pharmacokinetic limitations.

Looking forward, prioritizing the development of highly selective BET degraders, integrating predictive biomarkers such as MYC amplification or BRD4 dependency, and refining combination regimens stand as critical imperatives. Optimizing dosing to mitigate hematological adverse effects will be essential to unlock the full potential of BET-targeted therapies.

In summary, targeting BET proteins in solid tumors remains a vibrant and evolving frontier. First-generation inhibitors laid the conceptual groundwork, but overcoming inherent resistance and toxicity demands innovative next-generation molecules and strategic combinations. The path ahead hinges on biomarker-driven clinical trials and a deeper mechanistic understanding to translate this epigenetic vulnerability into tangible patient benefit.